Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease

Chikeka, Ijeuru; Grossman, Marc E.; Deng, Chao; Jacob, Alice T.; Husain, Sameera

doi:10.1016/j.jdcr.2019.11.007

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second patient, who had HIV-positive PBL, progressed after 8 cycles of EPOCH and remitted after 3 cycles of combination of dexamethasone, cisplatin, cytarabine (DHAP regimen), bortezomib, and daratumumab. ASCT and maintenance lenalidomide resulted in a sustained remission [ 32 ]. The third case presents a HIV-negative patient who developed PBL from chronic lymphocytic leukemia transformation.…”

Section: Discussionmentioning

confidence: 99%

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Lee

Martin

Abdulhaq

2022

Case Reports in Hematology

View full text Add to dashboard Cite

Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characterized by progressive bone loss and nonmalignant proliferation of vascular and lymphatic channels within the affected bone. Neither disease has a standard of care. We present a 23-year-old HIV-negative woman with GSD, managed medically with octreotide and sirolimus, who developed PBL. After progressing on V-EPOCH (bortezomib, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone), she was treated with daratumumab, lenalidomide, and dexamethasone (DRD) therapy and achieved complete remission after two cycles with progression after eight cycles. This is a report of treatment of PBL with DRD therapy. Clinical investigations of the DRD regimen in PBL in conjunction with other agents to improve both depth and durability of response are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Lee

Martin

Abdulhaq

2022

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…Other agents like lenalidomide, brentuximab vedotin, and Interleukin‐6‐directed agents have been shown to benefit in PBL in a few case reports 11,12 . Few case reports of daratumumab, an antibody directed against CD38, have shown activity in patients with relapsed PBL 13 . Daratumumab was added along with VR from cycle 3.…”

Section: Discussionmentioning

confidence: 99%

Relapsed plasmablastic lymphoma in a HIV‐negative patient: Pushing the envelope

Kathrotiya

Radhakrishnan

Bhave

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Other agents like lenalidomide, brentuximab vedotin, and Interleukin 6 directed agents have been shown to benefit in PBL in a few case reports (11,12) . Few case reports of daratumumab, an antibody directed against CD38, have shown activity in patients with relapsed PBL (13). Daratumumab was added along with VR from cycle 3.…”

Section: Discussionmentioning

confidence: 99%